369 related articles for article (PubMed ID: 31345392)
1. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
2. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
3. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
4. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
6. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
8. ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
Hutcherson RJ; Kemp MG
Mutat Res; 2019 Nov; 816-818():111678. PubMed ID: 31557599
[TBL] [Abstract][Full Text] [Related]
9. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
11. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
12. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
Dobler C; Jost T; Hecht M; Fietkau R; Distel L
Cells; 2020 Sep; 9(9):. PubMed ID: 32883016
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.
Karukonda P; Odhiambo D; Mowery YM
Mol Carcinog; 2022 Feb; 61(2):225-238. PubMed ID: 34964992
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
16. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
17. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
18. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
19. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]